Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Conditions: Severe Hemophilia A Interventions: Drug: FRSW117 Sponsors: Jiangsu Gensciences lnc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
Conditions: Severe Hemophilia A Interventions: Drug: FRSW107 Sponsors: Jiangsu Gensciences lnc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
Conditions: Severe Hemophilia A Interventions: Drug: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc) Sponsors: AryoGen Pharmed Co. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
Conditions: Hemophilia B Without Inhibitor Interventions: Drug: Low dose KL001; Drug: Middle dose KL001; Drug: High dose KL001 Sponsors: Affiliated Hospital of Guangdong Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)
Conditions: Hemophilia B Interventions: Genetic: ANB-002, dose 1; Genetic: ANB-002, dose 2 Sponsors: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
Conditions: Hemophilia B Without Inhibitor Interventions: Drug: Low dose KL001; Drug: Middle dose KL001; Drug: High dose KL001 Sponsors: Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
Conditions: Hemophilia A Interventions: Genetic: Single dose intravenous injection of BBM-H803 Sponsors: Shanghai Belief-Delivery BioMed Co., Ltd; Shanghai MYGT Biopharmaceutical LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
Conditions: Hemophilia A Interventions: Drug: Emicizumab Sponsors: Newark Beth Israel Medical Center; Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition
Conditions: Cerebral Microbleeds, Congenital Haemophilia, Congenital Von Willebrand Disease Interventions: Other: 3-Tesla brain MRI and a comprehensive neuropsychological assessment Sponsors: University Hospital, Lille Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the“Company” or“Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA)
Condition: Haemophilia Intervention: Sponsor: East Kent Hospitals University NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
